Savani Bipin N, Montero Aldemar, Wu Colin, Nlonda Nene, Read Elizabeth, Dunbar Cynthia, Childs Richard, Solomon Scott, Barrett A John
Stem Cell Allotransplant Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Biol Blood Marrow Transplant. 2005 Mar;11(3):223-30. doi: 10.1016/j.bbmt.2004.12.328.
Between July 1997 and August 2004, 146 consecutive patients with hematologic malignancies received a T cell-depleted peripheral blood stem cell transplant from an HLA-identical sibling by using total body irradiation (TBI) and cyclophosphamide conditioning regimens. Eighty-five patients received 13.6 Gy of TBI with no lung shielding, and 61 received lung shielding (total lung dose, 6-12 Gy). Ninety-four patients (65.5%) had standard-risk disease; the remainder had more advanced disease or unfavorable diagnoses. Of the 21 transplant-related deaths, 14 were from pulmonary causes (10 idiopathic pulmonary syndromes and 4 from infection) that occurred at a median of 90 days (range, 23-238 days) after transplantation. Independent risk factors for pulmonary transplant-related mortality (PTRM) were pretransplantation diffusion capacity for carbon monoxide (relative risk, 5.7 for diffusion capacity for carbon monoxide <85%), smoking (relative risk, 5.0), and CD34 cell dose (relative risk, 9.4 for a CD34 dose of <5 x 10(6) cells per kilogram). Patients receiving lung shielding had significantly lower PTRM (3.3% versus 14.1%; P = .02) and better overall survival (70% +/- 6% versus 52% +/- 5%; P = .04), but lung shielding was not a significant independent factor for determining PTRM. These results suggest that pulmonary mortality after TBI-based preparative regimens is predictable and that higher CD34 cell doses can reduce the risk.
1997年7月至2004年8月期间,146例连续性血液系统恶性肿瘤患者接受了来自 HLA 相同同胞的 T 细胞去除外周血干细胞移植,采用全身照射(TBI)和环磷酰胺预处理方案。85例患者接受了13.6 Gy 的 TBI,未进行肺部屏蔽,61例接受了肺部屏蔽(全肺剂量6 - 12 Gy)。94例患者(65.5%)患有标准风险疾病;其余患者病情更进展或诊断不佳。在21例与移植相关的死亡中,14例死于肺部原因(10例特发性肺部综合征和4例感染),发生在移植后中位时间90天(范围23 - 238天)。肺部移植相关死亡率(PTRM)的独立危险因素为移植前一氧化碳弥散能力(一氧化碳弥散能力<85%时相对风险为5.7)、吸烟(相对风险为5.0)和 CD34细胞剂量(CD34剂量<5×10⁶ 细胞/千克时相对风险为9.4)。接受肺部屏蔽的患者PTRM显著更低(3.3%对14.1%;P = 0.02)且总生存率更好(70%±6%对52%±5%;P = 0.04),但肺部屏蔽不是决定PTRM的显著独立因素。这些结果表明,基于TBI的预处理方案后的肺部死亡率是可预测的,且更高的CD34细胞剂量可降低风险。